my last buy on 9-14 @ $4.79 looking OK.

Bought more today @ $2.16

Iovance Biotherapeutics Director Wayne P. Rothbaum bought 5,000,000 shares of the company's stock in a transaction on Friday, September 15th. The shares were bought at an average cost of $5.30 per share, for a total transaction of $26,500,000.00.

Bought more IOVA today.

Survey: Do you think that MRKR should spend some money and advertise with some full page ads in the most prestigious medical journals like JAMA (Journal of the American Medical Association), The New England Journal of Medicine, Journal of Clinical Oncology in order to raise awareness of their Multi-TAA therapy, so that they can treat more patients and have quicker enrollment progress which hopefully would lead to a larger amount of postive result data?

Howdy DD, with all the $ that I am down in MRKR, I think the worst part is the patients that we might be saving if they knew about or were given the opportunity to be treated with Multi-TAA. If MRKR tech turns out to be a winner, then all those patients who could have been helped and were not due to lack of knowing about MRKR tech will be the real shame and not any amount of $ I'm down. The $ will follow the data, but I'm afraid that it will be too late for many people by then.

"after failing 4 prior lines of therapy, including anti-CD19 CAR T cell therapy, the participant demonstrated complete metabolic response based on PET-CT scans." Now we need to get the word out to other Doctors so that we can start treating and hopefully helping more patients. If it keeps showing that it works well, MT-601 needs to be the First Line of therapy and not 4th or 5th.

up 7% on 23,000 share volume, almost meaningless, but I'll take it.

Meant to say: Started a position today (8-24-23) at 25 cents. A bit risky, as a reverse SPLIT may be coming soon, also they just have cash to go through Q1 2024, but they are supposed to announce trial data Q3 2023, so pretty much, make or break.

Started a position today (8-24-23) at 25 cents. A bit risky, as a reverse may be coming soon, also they just have cash to go through Q1 2024, but they are supposed to announce trial data Q3 2023, so pretty much, make or break.

Phantom, this shows the problem with getting old. I (now) remember after reading your post, that just a couple/few weeks ago I read about the hypomethylating agents but when I was responding to GMA13 I completely forgot about that. Thanks, that makes sense.

Yeah, I wondered when I read "proposed changes", like what does that mean? It could be tweaking treatments or changing interim or final data reporting, changing primary endpoints or secondary endpoints or changing the number of patients to enroll up or down, but we ain't going to know until the FDA gives approval, so we go back to what we have been doing ... waiting.
And YES, a bit wordy but I'll take that compared to no response at all from P Hoang. Thanks again

Thank You GMA13 for sharing the response you got from Juan. I can't say that I am pleased with the delay but what he wrote seems to make sense. I just hope that there is GREAT news coming.

Thanks Again, excellent article. Looking out over the remainder of the year and early next year, Marker's CEO sees three main milestones. "The next set of news releases will be the readout on the AML patients, update on how we're collecting data on the lymphoma group and how these patients are responding to the therapy, and lastly, update and progression on the off-the-shelf program"

New institutional holdings out as of 6-30. No big changes.
WEDBUSH SECURITIES added 30,000 shares to the 12,000 they already owned.
The only interesting thing is:
91,733 Increased Total Shares Held
206,327 Decreased Total Shares Held
So, 114,594 shares went to retail investors

Thank You, You always have the correct and accurate information.

Yes, agree, the current PPS will be tested for durability. I hope we can stay at about the $5 price. Been sitting on cash to put in waiting for the "stategic review" to come out, so I guess I'll just keep waiting. Having said that, if the price bombs low again, I'll go in then without reading any stategic review. Hope that doesn't happen but if the opportunity comes, I'll take advantage of it.

I'm not positive about this but I don't think MRKR "the company" has any shares laying around that they could sell. If insiders sell, it raises money for the insiders, not the company. In order for MRKR to sell shares, they would of had to do an offering and dilute all the existing shareholders and that would not be good if they didn't have to. Also, in an offering, the share price offered is generally less than the current market price at the time.
As far as I know, no insiders did sell when the share price was much higher, so I guess that they still believe in the future potential.
Let's just hope they actually do have enough cash till end of 2025 and that we get some great data well before then.

Ok Thank You, my 3.6 mil was semiannually (5) not quarterly BUT I did NOT factor in the 9.7 grant $ remaining, thank you for pointing that out, so yes $2.8M per quarter. I guess, let's see what the Q3 report says. P.S. I'm pissed about the strategic review being push back months, I mean they know where they are and they know where they want to go, I could write the damn thing in an hour or less, what the hell?

"It has to be." ....... Great, just Great, here we go again, way to lose some of my confidence.

I must be missing something because I see all the time, big Pharm companies doing partnerships with tiny bio's that have a lot less data than MRKR and the dollar amount to just start a phase 1 would be nothing to a big Pharm compared to what they are spending on many other partnerships.

QUESTION: IF IF IF - "On June 26, 2023, Marker completed the previously announced non-dilutive transaction with Cell Ready, under which Cell Ready purchased certain cell manufacturing assets from Marker for approximately $19 million in cash." PLUS - "Marker received an additional $1 million in May 2023 per the Wilson Wolf Agreement" = 20 million ... THEN HOW - "Cash Position: At June 30, 2023, Marker had cash and cash equivalents of $18.1 million."
Were they down close to ZERO before the Cell Ready deal? In Dec 2022, they had 11.8 million cash and in March 2023 they had 6.4 million cash. Did they burn through the 6.4 million in one quarter? I guess so?
IN ORDER for the present 18.1 million to last through the end of 2025 as they say, they would need a cash burn rate of just 3.6 million per quarter going forward. We shall see.

MT-601 (Pancreatic) - "Clinical advancement will be pending additional financial support from non-dilutive grant activities."
Any chance of pursuing a partner for this program?

“Having made these broad-based advances in the second quarter, the new management team and I believe that Marker’s future has never been brighter. These advances position Marker to unlock significant value." gimme a M, gimme a R, gimme a K, gimme a R, rah, rah, rah, sounds great, now go win the ballgame.

“The second quarter of 2023 proved to be a highly beneficial time at Marker from an operational and clinical standpoint, and I am excited by our comprehensive strategic advancements,” commented Dr. Juan F. Vera
"In exchange for certain cell manufacturing assets, Cell Ready provided Marker with approximately $19 million in cash and Cell Ready will absorb approximately $11 million of Marker’s overhead expense annually while simultaneously ensuring that Marker’s manufacturing and research and development (R&D) needs will be fully met."
"we are finalizing an updated clinical development plan, which we expect to unveil in the coming months,” concluded Dr. Vera.

I wonder if the updated clinical development plan, which we expect to unveil in the coming months, is the stategic review due July/August?

19 million cash plus 11 million saved per year = value of 30 million for 2024 and 41 million for 2025?

MRKR news release
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2023-financial

Just to follow up, It seems like Multi-TAA (so far) have NO life threatening or fatal cytokine release syndrome should be a bigger deal than it is. I follow many different companies and their trial results. The CAR-T companies and the ADC (antibody drug conjugate) companies all seem to have this "severe adverse effects" problem of one kind or the other. Just looked at some results, 423 patients in one trial, 14 complete responses, which is good but is also about 3% CR's and they had 35% "severe adverse effects" which is very not good, as they would not only have a box warning (like Tavley) but also would only be available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) (like Tavley). Plus the cost of these CAR-T / ADC treatments will be in the 1/4 million to 1 million dollar range. I hope the FDA wises up to the benefits of Multi-TAA soon.

The FDA has granted "accelerated approval" for Talvey (Johnson & Johnson/Janssen), a new antibody-based therapy for adult patients with tough-to-treat blood cancers such as multiple myeloma. It has a Boxed Warning for life threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS).

Here's an idea, how about the FDA give Multi-TAA "accelerated approval" for AML as it does NOT create life threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS).

""" The strategic review and restructuring of our clinical programs is a comprehensive process. We are currently in the final stages of preparing this comprehensive review and plan to present it in late July/early August. Please be assured that we are working diligently to provide clear, comprehensive and timely information, and we are looking forward to sharing more about our exciting new directions in the coming weeks. Best regards, Juan """ ???

bought more today under $7.

Thanks for the info link.

OK, we had our "Virtual Roundtable", now when is our promised "Stategic Review"?

Bought more today again under $3

I share your frustration. Thanks

I hope so. Still waiting for the "stategic review".

Good news in an off the shelf treatment (in vitro) means less time and less cost to patients ... and the stock is down?

They are saying tested on solid tumor cancers, and it is Many years away even if it holds out to be true. I don't see any real threat to MRKR for blood cancers. Maybe Pancreatic as we are also just starting that one (again, IF AOH1996 turns out to work).

We have the 8-9 virtual roundtable soon. Also "supposed" to have stategic review from Juan Vera soon. Hopefully, one or both of them move the share price back up. Also on 8-15 we can see new institutional buyers as of 6-30 (but not for July which is what I really would like to see as that was a large part of the run up in price). If interested, updated the "my stocks" Ihub page.

Owned IOVA for a while, bought more today, still have open order to buy more if it drops below $7.

Bought more today under $3.